Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study
| Autor: | Bruna Angelelli, A. Rossi, Carlo Maurizio Camaggi, Antonello Franchini, Raffaella Comparsi, Elena Strocchi, Franco Pannuti |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
medicine.medical_specialty
Liver tumor Colorectal cancer medicine.medical_treatment Gastroenterology Hepatic Artery Pharmacokinetics Internal medicine medicine Humans Infusions Intra-Arterial Whole blood Aged Epirubicin Chemotherapy business.industry Rectal Neoplasms Liver Neoplasms Middle Aged medicine.disease Surgery Kinetics medicine.anatomical_structure Oncology Intravenous therapy Doxorubicin Colonic Neoplasms business Artery medicine.drug |
| Zdroj: | European journal of cancerclinical oncology. 22(11) |
| ISSN: | 0277-5379 |
| Popis: | Epirubicin (epiDX) pharmacokinetics was followed in 10 advanced cancer patients with hepatic metastases from colorectal carcinoma or primary liver tumor after single bolus administration (20–40 mg ) in the hepatic artery, through a surgically implanted catheter and subcutaneous access port. EpiDX plasma and whole blood concentrations follow a triphasic decay qualitatively similar to that observed after IV administration. Blood levels are consistently higher than plasma levels. Plasma clearance (nine patients, mean: 93.4 l/hr ; range: 69.3–129.5 l/hr ) is higher than the corresponding parameter determined in patients with hepatic metastases after intravenous therapy. The remaining patient is characterised by an abnormally low plasma clearance (13.6 l/hr ), due to a hepato-pulmonary shunt. The subjects in this study were exposed to very low drug concentrations, and therefore experienced no relevant adverse side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|